Quality Investor

Verisk Analytics, Inc.

Rank #93Capital Return

VRSK · Nasdaq · Industrials

Verisk Analytics, Inc. (VRSK) — Rank #93 by gross profitability (GP/assets 0.47) · ROE -77.8% · Piotroski F-Score 6 / 9.

As-of 2026-09-15 · CIK 0001442145 · all metrics point-in-time as of the filing date.

About

Verisk Analytics, Inc. engages in the provision of data analytics and technology solutions to the insurance industry in the United States and internationally.

Show more

The company offers underwriting solutions, including forms, rules, and loss costs services that provides policy language, prospective loss costs, policy writing and rating rules, and underwriting solutions for risk selection and segmentation, pricing, and workflow optimization; underwriting data and analytics solutions, which provides property and auto specific rating, and underwriting information solutions; catastrophe modelling and risk solutions; life insurance solutions for transforming current workflows in life insurance underwriting, claim insights, policy administration, unclaimed property/equity, compliance and fraud detection, and actuarial and portfolio modelling; specialty business solutions, which provides full end-to-end management of insurance and reinsurance business; and international underwriting solutions. It also provides claims insurance solutions, including property estimating solutions, provide data, analytics, and networking solutions for professionals involved in estimating all phases of building repair and reconstruction; anti-fraud solutions that provide fraud-detection tools for the property and casualty insurance industry; casualty solutions, which focus on compliance, casualty claims decision, and workflow automation; and international claims solutions, which focus on personal injury and motor franchises with complementary offerings to the property claims solutions.

The company was founded in 1971 and is headquartered in Jersey City, New Jersey.

Industry
Consulting Services
Sector
Industrials
State
DE
Filer Category
Large accelerated filer
Fiscal Year End
December 31
Website
verisk.com

Price History

VRSK-4.7% · -1.0% CAGRSPY+80.3% · +12.5% CAGR

Company Snapshot

P/E and reverse DCF are the primary valuation lenses at this stage.

Market Cap

$24.25B

P/E (annual)

28.6

P/S (annual)

7.9

P/B

P/OCF (annual)

16.9

Shareholder Yield

3.0%

Employees

8,000

Industry

Consulting Services

Exchange

Nasdaq

Signal Flags

2 green
Operating leverage expandingOperating income growing faster than revenue
Sequential beat (rev + EPS)Both revenue and EPS exceeded prior quarter — 1-quarter streak

Quality Profile

Profitability

1/1 pass
GP / assets
0.47
Return on equity
-77.8%
Gross margin trend
PASS

Safety

1/1 pass
Balance-sheet safety
PASS
Debt / equity
Current ratio
1.02×
Net cash
-$4.51B

Cash Flow

3/3 pass
Positive FCF
PASS
Cash-backed earnings
PASS
Accruals healthy
PASS
SBC / revenue
1.8%

Growth

2/2 pass
Revenue growth
6.6%
Piotroski F-Score
6 / 9
Share dilution
-1.9%

Terry Smith quality gate

Passes 4/5 Terry Smith thresholds

1 of 5 threshold not computable from filed data.

What Growth Is Priced In

Implied revenue growth (10Y)

8.9%

incredible deal

The annual FCF growth rate today's price requires over a 10-year horizon (discount rate 10%, terminal growth 2.5%).

Buyback tailwind: -1.9% — per-share value needs a total required return of 6.9% once share-count change is priced in.

vs. own 6-year median revenue growth: 7.1%

within its own history

Cost-of-equity sensitivity (implied growth at different discount rates)

r = 8%

4.5%

r = 10% (base)

8.9%

r = 12%

12.6%

Net debt / market cap: 17.4%

Note: current FCF margin is 2.6σ above its historical mean — implied growth may understate valuation risk if the margin reverts.

Base FCF: $1.2B3Y mean FCF: $980.9M

Valuation History

Current multiple vs historical range at each filing date. Band spans 25th-75th percentile.

P / E

Price / diluted EPS

28.4xCheap
28.4xmed 40.4x63.5x

P / S

Price / revenue per share

8.4xCheap
8.4xmed 10.8x14.3x

P / B

Price / book value per share

83.4xExpensive
10.1xmed 14.1x411.0x

P / GP

Price / gross profit per share

12.0xCheap
12.0xmed 16.4x20.8x

P / FCF

Price / free cash flow per share

21.6xCheap
21.6xmed 37.4x50.6x

FCF yield, shareholder yield, and buyback activity are the primary reads at this stage.

Profitability

Gross profitability (GP / assets)

0.47

Primary signal (Novy-Marx).

8th of 13 SIC 7374 peers

Return on equity

-77.8%

Gross margin

69.9%

7th of 13 SIC 7374 peers

Revenue growth (YoY)

6.6%

RPO growth (YoY)

-1.1%

Remaining performance obligations growth — RPO > revenue = forward demand building.

Gross margin improving

Margin trend vs prior year.

PASS

Operating Leverage

2022202320242025
Revenue vs COGS
Revenue vs OpEx
Op. Income vs Revenue

Growth

Revenue CAGR (3Y)

7.2%

Revenue CAGR (5Y)

6.2%

Earnings CAGR (3Y)

-1.6%

FCF CAGR (3Y)

15.0%

Anti-fragile safety

Balance-sheet safety

Composite anti-fragile check.

PASS

Debt / equity

Current ratio

1.02×

13th of 13 SIC 7374 peers

Quick ratio

0.91×

Net cash

-$4.51B

Cash & equivalents minus total debt.

Cash-flow health

Free cash flow

$1.19B

Operating cash flow minus capex.

Positive free cash flow

PASS

FCF / net income

0.31

Cash-backing of earnings.

FCF/NI divergence

Unfavorable divergence (yellow flag).

PASS

Accruals healthy

Cash-backed earnings.

PASS

SBC / revenue

1.8%

Stock-based comp intensity.

Dividend safety

Composite score

3.2 / 5

Good
Payout ratio
27.6%5/5 Strong
FCF coverage
4.75×5/5 Strong
Dividend growth streak
6 yr3/5 Good
Balance-sheet health
D/E N/A · IC N/A0/5 Weak

Piotroski F-Score

F-Score

6 / 9

Fundamental-strength score (0-9).

Lifecycle Phase History

20202025
Capital Return
Value